Neuropacs Closes Seed Round of Financing (Businesswire)
UF startup neuropacs™ Corp. announced the successful raise of over $1.0 million in early-stage capital.
Alachua County’s Bystander CPR Rates Save Lives, Study Finds (UF Health)
A study UF researchers published in the Journal of Clinical Medicine shows that following the local activation of PulsePoint, an app that alerts CPR-trained individuals about a nearby cardiac event, rates of bystander CPR performed outside a hospital setting significantly increased in Alachua County.
Solid Biosciences Doses First Patient in Phase 1b FALCON Trial for Friedreich’s Ataxia (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy for the treatment of Friedreich’s ataxia (FA).
UF/IFAS Awards $321K in AI Grants To Advance Ag-Tech Industry (UF/IFAS)
Five UF research teams were selected as recipients of the 2026 Launching Innovative Faculty Teams in AI funding program to advance AI research in agriculture.
Atsena Completes Part B Dosing and Advances to Pivotal Part C of LIGHTHOUSE Trial (Atsena Therapeutics)
UF startup Atsena Therapeutics announced that dosing is complete in patients enrolled across all adult and pediatric cohorts in Part B of the Phase I/II/III Lighthouse Trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Researchers Find Vital Clue in the Progression of Type 1 Diabetes (UF Health)
UF researchers have added an important piece to the puzzle in understanding the progression of type 1 diabetes.
With Startup, Researchers Plan To Help Growers Feed More People, Preserve Environment (UF News)
UF startup EZ Ag Innovations, founded by UF researchers Nathan Boyd and Arnold Schumann, is using AI-powered precision-spraying technology to help farmers reduce chemical use, lower costs, and improve sustainability in agriculture.
Rise Therapeutics Secures New Funding To Advance First-in-Class R-2487 Oral Immune Biomodulator Into Sjogren’s Disease Clinical Testing (Bio Space)
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, announced it will be initiating clinical evaluation of R-2487 in SjD.
Scientists Discover New Target in Potential Pancreatic Cancer Treatment (UF Health)
UF researchers helped find a promising new way to attack and kill pancreatic cancer cells by identifying an overlooked weak spot on a protein that supercharges the lethal cancer’s growth.
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics announced that dosing is complete in adults enrolled in Part B of the LIGHTHOUSE study, the Phase I/II/III clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).